The patch product comprises a membrane substrate suitable to be absorbed by the skin and based on natural polymers, as well as at least one active ingredient. It can be packaged in a wrapping comprising a support base, on which the patch product is placed, and a coating layer that acts as protection for the patch product.

The present invention relates to a transdermal nano-carrier and, more specifically, to a nano-carrier having a chitosan-based nano-sponge structure. According to the present invention, as a nano-carrier having enhanced transdermal delivery on the basis of a complex containing chitosan is provided, it is possible to effectively deliver drugs, cosmetic materials, etc. into the skin.

The present invention relates to a hypoxia-inducible factor (HIF) activator, or a pharmaceutically acceptable salt or solvate thereof, for use in promoting tissue repair. The HIF activator, or the pharmaceutically acceptable salt or solvate thereof, is for use with a prototypical tissue-protective cytokine, or a pharmaceutically acceptable salt or solvate thereof, which is administered exogenously to the body being treated.

Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a T.sub.max as quick as 2 minutes and not later than 30 minutes in the majority of subjects.

The invention relates to repeated treatment of a neuropathic condition, preferably peripheral neuropathic pain, by application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, to patients who previously did not respond or insufficiently responded to a previous application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches or any other high-concentration capsaicin and/or capsaicinoid formulation previously topically administered.

Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.

Procedures for targeted treatment of kidney fibrosis include administering to a subject in need of treatment of kidney fibrosis a compound including a plurality of nanoparticle including at least one BCL-2/BCL-xl inhibitor; at least one polymer comprising a member selected from the group consisting of PLGA, PEG or PVA; and at least one targeting peptide, wherein each of the plurality of nanoparticles defines a hollow shell formed by the polymer, the at least one BCL-2/BCL-xl inhibitor is located within an interior of the hollow shell, and the at least one targeting peptide is coupled to an exterior surface of the hollow shell.

The subject invention relates to compositions of a polyphenolic Polymer and methods useful for the delivery of substantially water-insoluble drugs and agrochemicals, like Artemisinin, Aspirin, and Pyrethrin. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary polyphenolic partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary polyphenol molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable. More important the whole process and material used is GRAS approved and environmentally safe.

The invention provides methods, compositions, and kits using a galectin-3 inhibitor to prevent and treat retinal nerve damage in a subject suffering from glaucoma.

The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.